Cargando…
Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning
Drug discovery is a challenging process with a huge molecular space to be explored and numerous pharmacological properties to be appropriately considered. Among various drug design protocols, fragment-based drug design is an effective way of constraining the search space and better utilizing biologi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291509/ https://www.ncbi.nlm.nih.gov/pubmed/35860028 http://dx.doi.org/10.3389/fphar.2022.920747 |
_version_ | 1784749151663161344 |
---|---|
author | Mukaidaisi, Muhetaer Vu, Andrew Grantham, Karl Tchagang, Alain Li, Yifeng |
author_facet | Mukaidaisi, Muhetaer Vu, Andrew Grantham, Karl Tchagang, Alain Li, Yifeng |
author_sort | Mukaidaisi, Muhetaer |
collection | PubMed |
description | Drug discovery is a challenging process with a huge molecular space to be explored and numerous pharmacological properties to be appropriately considered. Among various drug design protocols, fragment-based drug design is an effective way of constraining the search space and better utilizing biologically active compounds. Motivated by fragment-based drug search for a given protein target and the emergence of artificial intelligence (AI) approaches in this field, this work advances the field of in silico drug design by (1) integrating a graph fragmentation-based deep generative model with a deep evolutionary learning process for large-scale multi-objective molecular optimization, and (2) applying protein-ligand binding affinity scores together with other desired physicochemical properties as objectives. Our experiments show that the proposed method can generate novel molecules with improved property values and binding affinities. |
format | Online Article Text |
id | pubmed-9291509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92915092022-07-19 Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning Mukaidaisi, Muhetaer Vu, Andrew Grantham, Karl Tchagang, Alain Li, Yifeng Front Pharmacol Pharmacology Drug discovery is a challenging process with a huge molecular space to be explored and numerous pharmacological properties to be appropriately considered. Among various drug design protocols, fragment-based drug design is an effective way of constraining the search space and better utilizing biologically active compounds. Motivated by fragment-based drug search for a given protein target and the emergence of artificial intelligence (AI) approaches in this field, this work advances the field of in silico drug design by (1) integrating a graph fragmentation-based deep generative model with a deep evolutionary learning process for large-scale multi-objective molecular optimization, and (2) applying protein-ligand binding affinity scores together with other desired physicochemical properties as objectives. Our experiments show that the proposed method can generate novel molecules with improved property values and binding affinities. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9291509/ /pubmed/35860028 http://dx.doi.org/10.3389/fphar.2022.920747 Text en Copyright © 2022 Her Majesty the Queen in Right of Canada. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Mukaidaisi, Muhetaer Vu, Andrew Grantham, Karl Tchagang, Alain Li, Yifeng Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning |
title | Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning |
title_full | Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning |
title_fullStr | Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning |
title_full_unstemmed | Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning |
title_short | Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning |
title_sort | multi-objective drug design based on graph-fragment molecular representation and deep evolutionary learning |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291509/ https://www.ncbi.nlm.nih.gov/pubmed/35860028 http://dx.doi.org/10.3389/fphar.2022.920747 |
work_keys_str_mv | AT mukaidaisimuhetaer multiobjectivedrugdesignbasedongraphfragmentmolecularrepresentationanddeepevolutionarylearning AT vuandrew multiobjectivedrugdesignbasedongraphfragmentmolecularrepresentationanddeepevolutionarylearning AT granthamkarl multiobjectivedrugdesignbasedongraphfragmentmolecularrepresentationanddeepevolutionarylearning AT tchagangalain multiobjectivedrugdesignbasedongraphfragmentmolecularrepresentationanddeepevolutionarylearning AT liyifeng multiobjectivedrugdesignbasedongraphfragmentmolecularrepresentationanddeepevolutionarylearning |